Melodiol Global Health Limited

Equities

ME1

AU0000282840

Pharmaceuticals

Market Closed - Australian S.E. 01:10:10 2024-03-28 am EDT 5-day change 1st Jan Change
0.005 AUD +25.00% Intraday chart for Melodiol Global Health Limited +25.00% -87.50%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Melodiol Global Health Posts 148% Increase in FY 2023 Revenue to AU$21.6 Million MT
Melodiol Global Health Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Melodiol Unit to Add Cannabis Products Across Six Canadian Provinces MT
Melodial's Unit Logs AU$1 Million Revenues in January MT
Melodiol Global Health Limited Announces Resignation of Erlyn Dawson as Joint Company Secretary CI
Melodiol Global Health Limited Reports Unaudited Revenue Results for the Nine Months of 2023 CI
Melodiol Global's Canadian Arm Mernova Posts Record Sales for October MT
Melodiol Global Health Achieves 80% Remission Rate from Phase Two Hallucinogenic Trial MT
Melodial's Canadian Arm Mernova Logs Record Sales in Q3 MT
Melodiol Global Health Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Panacea Life Sciences Holdings, Inc. entered into a non-binding LOI to acquire Sierra Sages Herbs, LLC and Halucenex Life Sciences Inc. for $20 million. CI
Melodiol Logs Strong Start to Q3 with AU$1.6 Million in Revenue and Confirmed Purchase Orders MT
Melodiol Global Health Limited Announces Revenue Results for Third Quarter of 2023 CI
Melodiol Global Health Triples Q2 Net Sales MT
Creso Pharma Changes Name to Melodiol Global Health MT
Creso Pharma Signs Deal to Import Psychedelic Medication into Australia MT
Creso Pharma's Subsidiary Hires Consultant to Support Licensing Process in Australia, Europe MT
Creso Pharma Raises AU$2.5 Million Via Share Issue MT
ASX Halts Creso Pharma's Trading Amid Pending Announcement MT
Health House International to be Removed from Australian Bourse's Official List MT
Creso Pharma Limited completed the acquisition of Health House International Limited. CI
Creso Pharma Expands Pet Care Range to Asia with Distribution Deals MT
Creso Pharma Validates Efficacy of Psychedelic Drug in Phase 2 PTSD Trial MT
Creso Pharma Limited Auditor Raises 'Going Concern' Doubt CI
Melodiol Global Health Limited announced that it expects to receive AUD 2.5 million in funding from SBC Global Investors CI
Chart Melodiol Global Health Limited
More charts
Melodiol Global Health Limited, formerly Creso Pharma Limited, is an Australia-based cannabis company. The Company is engaged in developing cannabis and hemp-derived therapeutic-grade nutraceuticals and medical cannabis products with a range of applications in both human and animal health. Its cannabidiol (CBD) plant-based nutraceutical products are non-psychoactive, as they only contain trace amounts of tetrahydrocannabinol (THC). Its product is offered under various brands, including Green Goo, Southern Butter, Good Goo, Ritual, impactive and cannaQIX, among others. It cultivates and harvests cannabis plants through its subsidiary, Mernova Medicinal Inc. and supplies cannabis retail products throughout Canada. Through its wholly owned, Canada-based psychedelics subsidiary, Halucenex Life Sciences Inc., it is also focused on the development of synthetic and botanical psilocybin treatments for treatment-resistant post-traumatic stress disorder, and other mental health conditions.
More about the company
  1. Stock
  2. Equities
  3. Stock Melodiol Global Health Limited - Australian S.E.
  4. News Melodiol Global Health Limited
  5. Creso Pharma : Canadian Subsidiary Secures Purchase Orders; Shares Rally 10%